NO338310B1 - Sammensetninger og anvendelser av disse for behandling av prostata- og andre cancere - Google Patents

Sammensetninger og anvendelser av disse for behandling av prostata- og andre cancere Download PDF

Info

Publication number
NO338310B1
NO338310B1 NO20052055A NO20052055A NO338310B1 NO 338310 B1 NO338310 B1 NO 338310B1 NO 20052055 A NO20052055 A NO 20052055A NO 20052055 A NO20052055 A NO 20052055A NO 338310 B1 NO338310 B1 NO 338310B1
Authority
NO
Norway
Prior art keywords
cancer
hsp27
composition according
seq
therapeutic agent
Prior art date
Application number
NO20052055A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052055L (no
Inventor
Martin Gleave
Maxim Signaevsky
Palma Rocchi
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of NO20052055L publication Critical patent/NO20052055L/no
Publication of NO338310B1 publication Critical patent/NO338310B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20052055A 2002-10-02 2005-04-27 Sammensetninger og anvendelser av disse for behandling av prostata- og andre cancere NO338310B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41585902P 2002-10-02 2002-10-02
US46395203P 2003-04-18 2003-04-18
PCT/CA2003/001588 WO2004030660A2 (en) 2002-10-02 2003-10-02 Compositions for treatment of prostate and other cancers

Publications (2)

Publication Number Publication Date
NO20052055L NO20052055L (no) 2005-06-23
NO338310B1 true NO338310B1 (no) 2016-08-08

Family

ID=32073392

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20052055A NO338310B1 (no) 2002-10-02 2005-04-27 Sammensetninger og anvendelser av disse for behandling av prostata- og andre cancere
NO20160655A NO20160655A1 (no) 2002-10-02 2016-04-20 Sammensetninger og fremgangsmåter for behandling av prostata- og andre cancere

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20160655A NO20160655A1 (no) 2002-10-02 2016-04-20 Sammensetninger og fremgangsmåter for behandling av prostata- og andre cancere

Country Status (17)

Country Link
US (8) US7101991B2 (enExample)
EP (2) EP1545561B1 (enExample)
JP (2) JP5127138B2 (enExample)
KR (1) KR101142080B1 (enExample)
CN (1) CN1703229B (enExample)
AT (1) ATE465743T1 (enExample)
AU (1) AU2003278028B2 (enExample)
CA (1) CA2498026C (enExample)
DE (1) DE60332363D1 (enExample)
DK (1) DK1545561T3 (enExample)
ES (1) ES2345330T3 (enExample)
IL (1) IL167621A (enExample)
MX (1) MXPA05003551A (enExample)
NO (2) NO338310B1 (enExample)
NZ (1) NZ538841A (enExample)
WO (1) WO2004030660A2 (enExample)
ZA (1) ZA200502603B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538841A (en) * 2002-10-02 2006-10-27 Univ British Columbia Compositions for reducing hsp27 for the treatment of prostate and other cancers
US20060188508A1 (en) * 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
WO2007025229A2 (en) * 2005-08-25 2007-03-01 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hsp27
JP2009532017A (ja) * 2006-02-10 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア ＰＴＤ／ＣＰＰＳへのｄｓＲＮＡ結合ドメイン融合体によるｓｉＲＮＡの導入可能な送達
US8242258B2 (en) * 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
US9381209B2 (en) * 2007-03-05 2016-07-05 The University Of British Columbia Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy
WO2008112218A2 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
CA2656577A1 (en) * 2008-04-14 2009-10-14 The University Of British Columbia Method for evaluation of a cancer
CA2728762A1 (en) * 2008-07-02 2010-01-07 Enzon Pharmaceuticals, Inc. Rna antagonists targeting hsp27
CN102099041B (zh) * 2008-07-18 2013-07-31 Ogx科技公司 反义制剂
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
KR101217866B1 (ko) * 2010-08-18 2013-01-03 한국원자력의학원 혈관신생 억제용 약학 조성물 및 혈관신생 억제용 활성물질을 스크리닝하는 방법
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
JP5658696B2 (ja) * 2011-02-25 2015-01-28 株式会社ファンケル 皮膚のストレス蓄積度の評価方法
CA2747509C (en) 2011-05-12 2017-07-18 Oncogenex Technologies Inc. Treatment of pulmonary and pleural fibrosis using hsp27 inhibitors
US9717792B2 (en) 2012-02-02 2017-08-01 The University Of British Columbia Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates
GB201204785D0 (en) 2012-03-19 2012-05-02 Queen Mary & Westfield College Method for determining prognosis of prostate cancer in a subject
KR101374585B1 (ko) * 2012-05-02 2014-03-17 연세대학교 산학협력단 ＨＳＰ２７ 발현을 억제하는 ｓｈＲＮＡ
JP2015529073A (ja) 2012-08-20 2015-10-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物可逆性基を有するポリヌクレオチド
US20170216297A1 (en) 2014-07-28 2017-08-03 Technische Universitaet Dresden Efficient inhibition of hsp27
WO2017091885A1 (en) 2015-11-30 2017-06-08 The University Of British Columbia Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer
WO2019050948A1 (en) 2017-09-05 2019-03-14 Regeneron Pharmaceuticals, Inc. ADMINISTRATION OF A GENE EDITION SYSTEM HAVING ONLY ONE RETROVIRAL PARTICLE AND METHODS OF GENERATING AND USING

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09176011A (ja) * 1995-12-27 1997-07-08 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のフラボノイド含有合成抑制剤
WO2001070976A2 (en) * 2000-03-21 2001-09-27 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504766A (ja) * 1992-12-14 1996-05-21 スタート テクノロジー パートナーシップ ドーパミン作動性神経系の病態の診断および治療に関するドーパミン受容体ｍＲＮＡに対してアンチセンスのオリゴヌクレオチドの投与
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US20060008448A1 (en) * 1996-06-11 2006-01-12 Minzhen Xu Inhibition of li expression in mammalian cells
JPH107559A (ja) 1996-06-18 1998-01-13 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のベルベリン誘導体含有合成抑制剤
US5962262A (en) * 1997-07-25 1999-10-05 Incyte Pharmaceuticals, Inc. Human heat shock 27 like protein
US6703228B1 (en) 1998-09-25 2004-03-09 Massachusetts Institute Of Technology Methods and products related to genotyping and DNA analysis
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
ATE393220T1 (de) 1999-07-19 2008-05-15 Univ British Columbia Antisense-therapie für hormonregulierte tumoren
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003018758A2 (en) * 2001-08-23 2003-03-06 Arizona Board Of Regents Reagents and methods for smooth muscle therapies
NZ538841A (en) 2002-10-02 2006-10-27 Univ British Columbia Compositions for reducing hsp27 for the treatment of prostate and other cancers
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2007025229A2 (en) * 2005-08-25 2007-03-01 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hsp27
US9381209B2 (en) 2007-03-05 2016-07-05 The University Of British Columbia Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09176011A (ja) * 1995-12-27 1997-07-08 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のフラボノイド含有合成抑制剤
WO2001070976A2 (en) * 2000-03-21 2001-09-27 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DERWENT 1 January 1900 Derwent World Patents Index; AN 1997-399429, XP002272450, "Flavonoid containing protein synthesis inhibitor of HSP27 family protein - used in treatment of cancer resistant to hyperthermia and auto-immune disease such as multiple sclerosis" *
GARRIDO D. et al. Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells. The doxorubicin-protecting effect of Hsp27. Eur J Biochem. 1996, vol. 237. no. 3, side 653 – 659., Dated: 01.01.0001 *
GOTHAM S. Antisense and siRNA technologies--SMi Conference 12-13 February 2003, London, UK. IDrugs. 2003, vol. 6, no. 3, side 211-214., Dated: 01.01.0001 *
MORINO M. et al. Specific regulation of HSPs in human tumor cell lines by flavonoids.In Vivo. 1997, vol. 11, no. 3, side 265-270., Dated: 01.01.0001 *
TAMM I. et al. Antisense therapy in oncology: new hope for an old idea? Lancet. 2001, vol. 358, no. 9280, side 489-497., Dated: 01.01.0001 *

Also Published As

Publication number Publication date
US7847091B2 (en) 2010-12-07
US8772470B1 (en) 2014-07-08
US20160326527A1 (en) 2016-11-10
NZ538841A (en) 2006-10-27
EP1545561A2 (en) 2005-06-29
DK1545561T3 (da) 2010-08-02
US20040127441A1 (en) 2004-07-01
IL167621A (en) 2011-11-30
DE60332363D1 (de) 2010-06-10
WO2004030660A3 (en) 2004-06-10
US20060040886A1 (en) 2006-02-23
JP2006503904A (ja) 2006-02-02
US20150232843A1 (en) 2015-08-20
US20090221678A1 (en) 2009-09-03
US7723312B2 (en) 2010-05-25
ATE465743T1 (de) 2010-05-15
WO2004030660A2 (en) 2004-04-15
JP2010215669A (ja) 2010-09-30
US7550580B2 (en) 2009-06-23
AU2003278028A1 (en) 2004-04-23
JP5127138B2 (ja) 2013-01-23
JP5237996B2 (ja) 2013-07-17
KR101142080B1 (ko) 2012-05-03
EP2216029A3 (en) 2010-12-22
MXPA05003551A (es) 2005-10-19
ZA200502603B (en) 2006-06-28
US20060276424A1 (en) 2006-12-07
ES2345330T3 (es) 2010-09-21
US7101991B2 (en) 2006-09-05
EP2216029A2 (en) 2010-08-11
EP1545561B1 (en) 2010-04-28
US9580712B2 (en) 2017-02-28
AU2003278028B2 (en) 2008-12-18
US20140315978A1 (en) 2014-10-23
NO20160655A1 (no) 2016-04-20
US9085769B2 (en) 2015-07-21
CN1703229A (zh) 2005-11-30
CA2498026C (en) 2015-06-30
NO20052055L (no) 2005-06-23
CN1703229B (zh) 2011-01-05
KR20050050111A (ko) 2005-05-27
CA2498026A1 (en) 2004-04-15
US9404109B2 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
US9580712B2 (en) Compositions and methods for treatment of prostate and other cancers
US7820635B2 (en) RNAi probes targeting cancer-related proteins
EP3384028B1 (en) Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer
US8722872B2 (en) Compositions and methods for treatment of prostate and other cancers
US9879255B2 (en) Modulation of RNA activity and vascular permeability
AU2007216630B2 (en) RNAi probes targeting cancer-related proteins

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees